2018AISF_SIMI_SIMIT_SIN立场声明_慢性肾脏病患者丙型肝炎感染的管理.pdf

Infection /10.1007/s15010-018-1209-2 POSITION PAPERS AND GUIDELINES Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN) 1 2,3 4 5 6 Roberto Minutolo  · Alessio Aghemo  · Antonio Chirianni  · Fabrizio Fabrizi  · Loreto Gesualdo  · 7 8 6 9 10 Edoardo G. Giannini  · Paolo Maggi  · Vincenzo Montinaro  · Ernesto Paoletti  · Marcello Persico  · Francesco Perticone11 · Salvatore Petta12 · Massimo Puoti13 · Giovanni Raimondo14 · Maria Rendina15 · Anna Linda Zignego16 · on behalf of the Italian Society of Nephrology (SIN) · the Italian Association for the Study of the Liver (AISF) · the Italian Society of Infectious and Tropical Disease (SIMIT) · the Italian Society of Internal Medicine (SIMI) Received: 28 March 2018 / Accepted: 9 August 2018 © The Author(s) 2018 Abstract Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively afects the prognosis of renal patients. In the last few years, availability of more speciic and efective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recip